Articles related to HEART ATTACK/MYOCARDIAL INFARCTION

A network meta-analysis of 24 trials (16,371 patients) found complete revascularization in myocardial infarction with multivessel disease reduced all-cause mortality by 15% compared to culprit-only revascularization, suggesting potential improved outcomes for this population.

A recent study involving 4,400 participants revealed that two major statins—rosuvastatin and atorvastatin—are equally effective at reducing heart attacks, strokes, and all-cause deaths. However, it was found that the rosuvastatin group was more likely (7.2%) to develop type 2 diabetes than the atorvastatin group (5.3%).

In this video, Zack Shinar, MD, discusses the future of cardiac arrest and the role of extracorporeal membrane oxygenation (ECMO) in the emergency department (ED). Dr. Shinar is a leading expert in ECMO and has been instrumental in developing new protocols for its use in the ED. Dr. Shinar begins by discussing the current state of CPR. He notes that CPR is only effective in about 10% of cases, and that even when it is successful, patients often suffer significant brain damage. He then discusses ECMO, which is a life-support machine that can oxygenate the blood outside of the body. ECMO has been shown to be effective in saving the lives of patients with cardiac arrest, and Dr. Shinar believes that it should be used more widely in the ED. Dr. Shinar then discusses the challenges of using ECMO in the ED. He notes that ECMO is a complex procedure that requires specialized training and equipment. He also notes that ECMO can be expensive, and that it is not always available in all hospitals.

Danish researchers assembled a prospective observational cohort study of 9,533 asymptomatic people aged 40 years or older with no known ischemic heart disease to define characteristics of subclinical coronary atherosclerosis associated with the development of myocardial infarction. The study’s findings are startling.

Questions run across a host of topics, and in September you can challenge yourself in mortality risk, myocardial infarction (MI), insomnia, liver cancer, lipids, and Parkinson’s disease guidelines. Each question is worth 4 points with bonuses for quick response. Speed matters in this quiz. Why not give it a try and see if you can get on the leaderboard of the Smartest Doc?

To assess short-term risk for severe cardiovascular events (excluding myocarditis and pericarditis) after COVID-19 vaccination, adults younger than 75 years hospitalized for PE, acute MI, hemorrhagic stroke, or ischemic stroke (73,325 events) were reviewed in relation to a 1st or 2nd COVID vaccine dose. No association was found between the Pfizer–BioNTech or Moderna vaccine and severe cardiovascular events. The first dose of the Oxford–AstraZeneca vaccine was associated with acute MI and PE in the second week after vaccination. An association with MI in the second week after a single dose of the Janssen vaccine could not be ruled out.